—
C+
C+ The full Closelook — membership. Open the C+ overview

Amgen Inc (AMGN) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — Amgen Inc

AMGN in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Amgen discovers, develops and manufactures human therapeutics, with products spanning rheumatoid arthritis, osteoporosis, cardiovascular risk reduction and rare diseases such as Enbrel, Prolia and Repatha. It sells through pharmaceutical wholesale distributors to hospitals, clinics and pharmacies worldwide. It is headquartered in Thousand Oaks, California.
Where it sits in the stack
Amgen sits in our HALO Growth 100 index, in the Longevity & Healthspan sleeve, which groups GLP-1 leaders, gene-editing platforms, diagnostics-at-scale and biopharma compounders. Within that sleeve it functions as a broad-portfolio compounder, supplying chronic-disease treatments to a demand curve set by an ageing population rather than a single therapeutic bet.
Who it is priced against
Closelook's peer group places it with Eli Lilly, Regeneron, Zealand Pharma, Vertex, Illumina, Novo Nordisk, Natera and Gerresheimer, on the reasoning that demographics drives demand across the group; the market also compares it with Pfizer.
Why Closelook tracks it
Amgen holds a seat in our HALO Growth 100, and also sits in the Nasdaq-100 and the Dow Jones Industrial Average. It carries a Closelook score, strongest on the quality module and weakest on valuation. The Morning 10 has quoted it once, noting a sharp single-day drop during a broader Wall Street sell-off.
What the diary watches
The diary watches whether the valuation module stays the weak point as the quality score holds, and whether the recent downgrade to Hold from Buy marks a shift in how the market reads the stock.

Amgen Inc (AMGN) trades on US exchanges, classified under Healthcare. Constituent of HALO Growth 100.

The Closelook company score reads 54/100 composite (momentum 71, quality 84, valuation 43) across 7 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: AMGN news on the tape · index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for AMGN, from the same nightly bakes the boards use. Research diary readings, not advice.

The Street on this name 7 analyst actions on the wire · latest: price target by Jefferies, 2026-09-23

The Street on this name

Analyst actions and the latest print for AMGN from the Closelook wires — third-party opinions on the record, not our readings.

  • Price target Jefferies — target 410 Target set to $410 (-0.1% to spot) 2026-09-23
  • Price target UBS — target 430 Target set to $430 (+13.6% to spot) 2026-09-17
  • Price target Piper Sandler — target 457 from 427 Target raised to $457 from $427 (+3.3% to spot) 2026-08-20

7 actions on the analyst wire since 2026-08-13: 7 target changes. Analyst wire → · Earnings wire →

Who it is priced against HALO Growth 100 · Longevity & Healthspan · 8 names with week and year-to-date

Peer group

HALO Growth 100 · Longevity & Healthspan

GLP-1 leaders, gene-editing platforms, diagnostics-at-scale, biopharma compounders. Demographics writes the demand curve.

Compared against AMGN on the nightly bakes; the Peers tab ranks the cohort on the Closelook scores where it exists.

Versus its index HALO Growth 100 — the name, its sleeve and the index over day, week and month

Versus its index

The name against its Closelook index and its own sleeve — equal-weight, nightly closes.

HALO Growth 100 · as of 2026-09-24

DayWeekMonth3 months
AMGN−1.2%+6.9%−8.2%+15.1%
Longevity & Healthspan+0.6%+4.2%+0.8%—
HALO Growth 100−0.8%−0.5%−7.7%—

Against the index: 7.4 pts ahead on the week, 0.5 pts behind on the month; against its Longevity & Healthspan sleeve 9.0 pts behind on the month.

Returns from the index workers’ nightly closes; equal-weight sleeves. A relative reading from the research diary, not advice.

Dividends and capital return trailing yield 2.45%, quarterly · last 2.52 USD on 2026-08-21

Dividends and capital return

What AMGN pays out and buys back — distributions read from the price series, money terms from the filings.

  • Trailing 12 months 9.94 USD per share · a 2.45% yield on the 2026-09-24 close 4 distributions, paid quarterly 2026-09-24
  • Change on the year +5.9% against the prior twelve months prior twelve months 9.39 USD per share
  • Last distribution 2.52 USD per share as the price series records it, within days of the ex-date 2026-08-21
  • By calendar year 2023: 2.13 USD (partial) · 2024: 9.00 USD · 2025: 9.52 USD · 2026: 7.56 USD to date first distribution recorded in the three-year window: 2023-11-16
  • Dividends paid, FY2025 5.12 bn USD 44% of earnings
  • Buybacks, FY2025 none reported
  • Share count +0.2% in FY2025 494 m USD of stock-based compensation in the year
  • Capital returned 5.12 bn USD · 63% of free cash flow dividends and buybacks together, against the year’s free cash flow

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

How it trades on rate days beta 0.47 to TLT · on the worst bond days it moved with the market

How it trades on rate days

How AMGN has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 0.47 — tends to move with bonds for every 1% move in TLT (20+ year Treasuries), Amgen Inc moved 0.47% on average · correlation 0.15 · higher than 49% of US names
  • Beta, last 3 months 0.90 more rate-sensitive lately than over the year
  • On the 10 worst bond days −0.86% on average against −0.74% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days −0.01% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Weather around the name 4 macro readings: Money Temperature, Factor regime, Sector × region …

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 60/100 · S&P 500 fund at 66, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-24
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 99th percentile of the window, +10.1% over 20 sessions. Factor regime → 2026-09-24
  • Sector × region Health care in US: +1.0% week · −2.7% month · +9.6% quarter · +11.5% yearThe Sector Engine cell this name lives in, from XLV.US; the 11 × 4 matrix shows where its sector is being bought and where it is being sold. Sector Engine → 2026-09-24
  • Sovereign pressure Index 0.60 · up 0.32 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-23

FAQ · from the current data · as of 2026-09-25

Quick answers

What is Amgen Inc (AMGN)?

Amgen Inc trades as AMGN on the US exchange (US) and is classified under Healthcare in the Closelook research universe, as of the registry build of 2026-09-25.

Is AMGN in a Closelook index?

Yes — Amgen Inc is a constituent of HALO Growth 100, as of 2026-09-25.

What is Amgen Inc's Closelook composite score?

54 out of 100, with momentum 71, quality 84 and valuation 43 sub-scores, as of 2026-09-25. Scores are Closelook's own research readings, not ratings or investment advice.

Where does AMGN trade against its moving averages?

Reclaimed its 50-day: Closed back above its 50-day line 2 sessions ago, with the 200-day still rising beneath it. As of 2026-09-23 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

How is AMGN doing against its Closelook index?

Over the past month Amgen Inc is −8.2% against −7.7% for the HALO Growth 100 — 0.5 points behind its index, as of 2026-09-24. Its Longevity & Healthspan sleeve is +0.8% over the same month. The “Versus its index” table on this page carries the day, the week and the month for the name, its sleeve and the index.

What does Amgen Inc do?

Amgen discovers, develops and manufactures human therapeutics, with products spanning rheumatoid arthritis, osteoporosis, cardiovascular risk reduction and rare diseases such as Enbrel, Prolia and Repatha. It sells through pharmaceutical wholesale distributors to hospitals, clinics and pharmacies worldwide. It is headquartered in Thousand Oaks, California. Closelook's peer group places it with Eli Lilly, Regeneron, Zealand Pharma, Vertex, Illumina, Novo Nordisk, Natera and Gerresheimer, on the reasoning that demographics drives demand across the group; the market also compares it with Pfizer.

Where does Amgen Inc sit in the AI build-out?

Amgen sits in our HALO Growth 100 index, in the Longevity & Healthspan sleeve, which groups GLP-1 leaders, gene-editing platforms, diagnostics-at-scale and biopharma compounders. Within that sleeve it functions as a broad-portfolio compounder, supplying chronic-disease treatments to a demand curve set by an ageing population rather than a single therapeutic bet. Amgen holds a seat in our HALO Growth 100, and also sits in the Nasdaq-100 and the Dow Jones Industrial Average. It carries a Closelook score, strongest on the quality module and weakest on valuation. The Morning 10 has quoted it once, noting a sharp single-day drop during a broader Wall Street sell-off.

Does Amgen Inc pay a dividend?

Amgen Inc has paid 9.94 USD per share over the last twelve months, paid quarterly, a trailing yield of 2.45% on the 2026-09-24 close; the last distribution recorded in the price series was 2.52 USD on 2026-08-21. In fiscal 2025 the company paid 5.12 bn USD in dividends, 63% of that year’s free cash flow. The share count rose 0.2% over the fiscal year. The "Dividends and capital return" block on this page carries the lines.

How does Amgen Inc trade when bond yields rise?

Over the past year Amgen Inc had a beta of 0.47 to TLT, the long-dated Treasury fund — it tends to move with bonds, higher than 49% of US names. On the 10 sessions in which long bonds fell most it moved −0.86% on average, against −0.74% for the S&P 500. The "How it trades on rate days" block on this page carries the lines.

What has Wall Street done on Amgen Inc recently?

The most recent analyst action on Amgen Inc on the Closelook wire is a price target by Jefferies on 2026-09-23 (target 410). 7 actions on the analyst wire since 2026-08-13: 7 target changes. Analyst actions are third-party opinions recorded by the wire, not Closelook readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

Where has Closelook written about Amgen Inc?

Amgen Inc appears in 1 Closelook piece, most recently Morning 10: Oil knocks on $100 and Wall Street sells everything but the AI pipe: Intel +9%, Lumentum +11%, Dow −1.2% — Seoul buys the dip and the Kospi is back above 7,000 (2026-09-09). What Closelook said most recently: Wall Street came back from the long weekend and sold: the Dow lost 1.2%, the S&P 500 0.6%, the Nasdaq 0.3%, with Amgen −10% and Salesforce −4% doing the damage. (Morning 10, 2026-09-09). The "Mentioned on Closelook" block on this page lists the long reads, the reference entries and the dailies that name it.

What does this page show?

A live price chart with SMA overlays and drawing tools for AMGN, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Mentioned on Closelook 1 piece · newest: Morning 10, “Oil knocks on $100 and Wall Street sells everything but the AI pipe: Intel +9%, Lumentum +11%, Dow −1.2% — Seoul buys the dip and the Kospi is back above 7,000” (2026-09-09)

Mentioned on Closelook

Where AMGN appears in the diary — 1 piece, newest first. Every link is our own writing.

Dailies

Related in the Closelook universe

same Closelook index seat first, then Drug Manufacturers - General. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.